MedPath

Dextromethorphan in Treating Patients With Fatigue Caused by Cancer

Not Applicable
Terminated
Conditions
Fatigue
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific
Registration Number
NCT00176540
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Brief Summary

RATIONALE: Dextromethorphan may help relieve fatigue in patients with cancer.

PURPOSE: This clinical trial is studying how well dextromethorphan works in treating patients with fatigue caused by cancer.

Detailed Description

OBJECTIVES:

Primary

* Assess the effects of dextromethorphan hydrobromide in patients with cancer-related fatigue.

Secondary

* Correlate the changes in cancer-related fatigue with the levels of plasma homocysteine versus red blood cell folate.

OUTLINE: This is a multicenter, open-label, pilot study.

Patients receive oral dextromethorphan hydrobromide 3 times a day on days 1-7. Treatment repeats weekly for up to 3 weeks in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy
Secondary Outcome Measures
NameTimeMethod
Correlation of the changes in cancer-related fatigue with the levels of plasma homocysteine versus red blood cell folate

Trial Locations

Locations (2)

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

🇺🇸

New Brunswick, New Jersey, United States

Cancer Institute of New Jersey at Hamilton

🇺🇸

Hamilton, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath